Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emmanuel Gyan

Showing results (61-70 of 174) with videos related to

Pageof 18
Sort By:
Blood|March 3, 2017
Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association reportMira Tout, Olivier Casasnovas, Michel Meignan, et al.
Pharmacological Research|August 25, 2018
n-3 Polyunsaturated fatty acids induce acute myeloid leukemia cell death associated with mitochondrial glycolytic switch and Nrf2 pathway activationFrédéric Picou, Christelle Debeissat, Jérôme Bourgeais, et al.
Leukemia Research Reports|July 29, 2014
An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromesStuart L Goldberg, Pierre Fenaux, Michael D Craig, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|February 9, 2026
Which trial do we need? Defining the optimal duration of antifungal therapy for invasive pulmonary aspergillosis: duration of therapy in invasive aspergillosisGuillaume Desoubeaux, Malgorzata Mikulska, Adrien Lemaignen, et al.
Annals of Hematology|July 1, 2020
Safety and efficacy of temsirolimus in combination with three different immuno-chemotherapy regimens in relapse and refractory mantle cell lymphoma, final results of the T<sup>3</sup> phase IB trial of the LYSABenoît Tessoulin, Kamal Bouabdallah, Barbara Burroni, et al.
Haematologica|December 7, 2007
Outcome of adult T-lymphoblastic lymphoma after acute lymphoblastic leukemia-type treatment: a GOELAMS trialMathilde Hunault, Malgorzata Truchan-Graczyk, Denis Caillot, et al.
British Journal of Haematology|April 30, 2021
No survival improvement in patients with high-risk multiple myeloma harbouring del(17p) and/or t(4;14) over the two past decadesThomas Chalopin, Nicolas Vallet, Olivier Theisen, et al.
Blood Advances|December 24, 2019
Bone marrow oxidative stress and specific antioxidant signatures in myelodysplastic syndromesFrederic Picou, Christine Vignon, Christelle Debeissat, et al.
European Journal of Clinical Investigation|November 2, 2024
Glycolytic activity following anti-CD19 CAR-T cell infusion in non-Hodgkin lymphomaNicolas Vallet, Laurianne Drieu Larochelle, Maria-Joao Santiago-Ribeiro, et al.
Leukemia Research|November 8, 2017
Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidineMarie Sébert, Rami S Komrokji, Mikkael A Sekeres, et al.
Pageof 18

Showing results (61-70 of 174) with videos related to

Sort By:
Pageof 18
Blood|March 3, 2017
Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association reportMira Tout, Olivier Casasnovas, Michel Meignan, et al.
Pharmacological Research|August 25, 2018
n-3 Polyunsaturated fatty acids induce acute myeloid leukemia cell death associated with mitochondrial glycolytic switch and Nrf2 pathway activationFrédéric Picou, Christelle Debeissat, Jérôme Bourgeais, et al.
Leukemia Research Reports|July 29, 2014
An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromesStuart L Goldberg, Pierre Fenaux, Michael D Craig, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|February 9, 2026
Which trial do we need? Defining the optimal duration of antifungal therapy for invasive pulmonary aspergillosis: duration of therapy in invasive aspergillosisGuillaume Desoubeaux, Malgorzata Mikulska, Adrien Lemaignen, et al.
Annals of Hematology|July 1, 2020
Safety and efficacy of temsirolimus in combination with three different immuno-chemotherapy regimens in relapse and refractory mantle cell lymphoma, final results of the T<sup>3</sup> phase IB trial of the LYSABenoît Tessoulin, Kamal Bouabdallah, Barbara Burroni, et al.
Haematologica|December 7, 2007
Outcome of adult T-lymphoblastic lymphoma after acute lymphoblastic leukemia-type treatment: a GOELAMS trialMathilde Hunault, Malgorzata Truchan-Graczyk, Denis Caillot, et al.
British Journal of Haematology|April 30, 2021
No survival improvement in patients with high-risk multiple myeloma harbouring del(17p) and/or t(4;14) over the two past decadesThomas Chalopin, Nicolas Vallet, Olivier Theisen, et al.
Blood Advances|December 24, 2019
Bone marrow oxidative stress and specific antioxidant signatures in myelodysplastic syndromesFrederic Picou, Christine Vignon, Christelle Debeissat, et al.
European Journal of Clinical Investigation|November 2, 2024
Glycolytic activity following anti-CD19 CAR-T cell infusion in non-Hodgkin lymphomaNicolas Vallet, Laurianne Drieu Larochelle, Maria-Joao Santiago-Ribeiro, et al.
Leukemia Research|November 8, 2017
Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidineMarie Sébert, Rami S Komrokji, Mikkael A Sekeres, et al.
Pageof 18